[go: up one dir, main page]

WO2004009590A8 - 4-aminosubstituierte pyrimidinderivate - Google Patents

4-aminosubstituierte pyrimidinderivate

Info

Publication number
WO2004009590A8
WO2004009590A8 PCT/EP2003/007236 EP0307236W WO2004009590A8 WO 2004009590 A8 WO2004009590 A8 WO 2004009590A8 EP 0307236 W EP0307236 W EP 0307236W WO 2004009590 A8 WO2004009590 A8 WO 2004009590A8
Authority
WO
WIPO (PCT)
Prior art keywords
amino
pyrimidine derivatives
substituted pyrimidine
production
medicaments
Prior art date
Application number
PCT/EP2003/007236
Other languages
English (en)
French (fr)
Other versions
WO2004009590A1 (de
Inventor
Achim Feurer
Joachim Luithle
Stephan-Nicholas Wirtz
Gerhard Koenig
Johannes-Peter Stasch
Elke Stahl
Rudy Schreiber
Frank Wunder
Dieter Lang
Original Assignee
Bayer Healthcare Ag
Achim Feurer
Joachim Luithle
Stephan-Nicholas Wirtz
Gerhard Koenig
Johannes-Peter Stasch
Elke Stahl
Rudy Schreiber
Frank Wunder
Dieter Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Achim Feurer, Joachim Luithle, Stephan-Nicholas Wirtz, Gerhard Koenig, Johannes-Peter Stasch, Elke Stahl, Rudy Schreiber, Frank Wunder, Dieter Lang filed Critical Bayer Healthcare Ag
Priority to CA002492726A priority Critical patent/CA2492726A1/en
Priority to JP2004522410A priority patent/JP2005537274A/ja
Priority to EP03740426A priority patent/EP1525203A1/de
Priority to AU2003281477A priority patent/AU2003281477A1/en
Priority to US10/521,540 priority patent/US7410973B2/en
Publication of WO2004009590A1 publication Critical patent/WO2004009590A1/de
Publication of WO2004009590A8 publication Critical patent/WO2004009590A8/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Die vorliegende Erfindung betrifft neue 4-Aminosubstituierte Pyrimidin-Derivate, welche die lösliche Guanylatcyclase stimulieren, Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln, insbesondere von Arzneimittel zur Behandlung von Krankheiten des Zentralnervensystems.
PCT/EP2003/007236 2002-07-18 2003-07-07 4-aminosubstituierte pyrimidinderivate WO2004009590A1 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002492726A CA2492726A1 (en) 2002-07-18 2003-07-07 4-amino-substituted pyrimidine derivatives
JP2004522410A JP2005537274A (ja) 2002-07-18 2003-07-07 ４−アミノ置換ピリミジン誘導体
EP03740426A EP1525203A1 (de) 2002-07-18 2003-07-07 4-aminosubstituierte pyrimidinderivate
AU2003281477A AU2003281477A1 (en) 2002-07-18 2003-07-07 4-amino-substituted pyrimidine derivatives
US10/521,540 US7410973B2 (en) 2002-07-18 2003-07-07 4-amino-substituted pyrimidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10232571.5 2002-07-18
DE10232571A DE10232571A1 (de) 2002-07-18 2002-07-18 4-Aminosubstituierte Pyrimidinderivate

Publications (2)

Publication Number Publication Date
WO2004009590A1 WO2004009590A1 (de) 2004-01-29
WO2004009590A8 true WO2004009590A8 (de) 2005-05-12

Family

ID=30010151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007236 WO2004009590A1 (de) 2002-07-18 2003-07-07 4-aminosubstituierte pyrimidinderivate

Country Status (7)

Country Link
US (1) US7410973B2 (de)
EP (1) EP1525203A1 (de)
JP (1) JP2005537274A (de)
AU (1) AU2003281477A1 (de)
CA (1) CA2492726A1 (de)
DE (1) DE10232571A1 (de)
WO (1) WO2004009590A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026392A1 (de) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
EP2549875B1 (de) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Lösliche guanylat-cyclase-aktivatoren
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
EP2590987B1 (de) 2010-07-09 2016-03-09 Bayer Intellectual Property GmbH Annellierte 4-aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase
AU2011275825A1 (en) 2010-07-09 2013-02-07 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102010043380A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Benzyl-substituierte Carbamate und ihre Verwendung
CN103619845B (zh) 2011-04-21 2016-08-17 拜耳知识产权有限责任公司 氟烷基取代的吡唑并吡啶及其用途
EA026701B1 (ru) 2011-09-02 2017-05-31 Байер Интеллектуэль Проперти Гмбх Замещенные аннелированные пиримидины, способ их получения, их применение и лекарственное средство для лечения и/или профилактики заболеваний
DE102011082041A1 (de) 2011-09-02 2013-03-07 Bayer Pharma AG Substituierte annellierte Pyrimidine und ihre Verwendung
DE102012200351A1 (de) 2012-01-11 2013-07-11 Bayer Pharma Aktiengesellschaft Substituierte annellierte Pyrimidine und ihre Verwendung
CR20190057A (es) 2011-11-25 2019-04-23 Adverio Pharma Gmbh PROCEDIMIENTO DE PREPARACIÓN DE 5-FLUORO-1H-PIRAZOLOPIRIDINAS SUSTITUIDAS (Divisional 2014-0237)
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
DE102012200352A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
JP6140738B2 (ja) 2012-03-06 2017-05-31 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アザ二環およびその使用
WO2014128109A1 (en) 2013-02-21 2014-08-28 Bayer Pharma Aktiengesellschaft Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
CN105026405B (zh) * 2013-03-01 2017-08-08 拜耳制药股份公司 苄基‑取代的吡唑并吡啶及其用途
AP2015008637A0 (en) 2013-03-01 2015-08-31 Bayer Pharma AG Trifluormethyl-substituted ring-fused pyrimidines and use thereof
TW201542569A (zh) 2013-07-10 2015-11-16 Bayer Pharma AG 苯甲基－１Ｈ－吡唑并［３，４－ｂ］吡啶類及其用途
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US20170240566A1 (en) 2014-08-29 2017-08-24 Bayer Pharma Aktiengesellschaft Amino-substituted annulated pyrimidines and use thereof
CN107108658A (zh) 2014-08-29 2017-08-29 拜耳医药股份有限公司 取代的环状嘧啶及其用途
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
WO2017121700A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase
WO2017121692A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte sulfamide und ihre verwendung
WO2017121693A1 (de) 2016-01-15 2017-07-20 Bayer Pharma Aktiengesellschaft Substituierte thiazol- und thiadiazolamide und ihre verwendung
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
JP7542518B2 (ja) 2018-07-11 2024-08-30 ティセント セラピューティクス インコーポレーテッド ミトコンドリア（ｍｉｔｏｃｈｏｎｒｉａｌ）障害の処置のためのｓＧＣ刺激剤の使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834045A1 (de) * 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
DE19846514A1 (de) * 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina

Also Published As

Publication number Publication date
AU2003281477A1 (en) 2004-02-09
CA2492726A1 (en) 2004-01-29
DE10232571A1 (de) 2004-02-05
JP2005537274A (ja) 2005-12-08
US7410973B2 (en) 2008-08-12
WO2004009590A1 (de) 2004-01-29
EP1525203A1 (de) 2005-04-27
US20060014951A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2004009590A8 (de) 4-aminosubstituierte pyrimidinderivate
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
MY136841A (en) Carbamate-substituted pyrazolopyridines
IL163102A (en) Dihydrobenzodiazepin-2-one derivatives, process for their preparation and use thereof in the preparation of medicaments for the treatment of neurological disorders
WO2003080582A3 (de) Fredericamycin-derivate
WO2003092580A3 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2004078116A3 (en) P38 inhibitors and methods of use thereof
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
MY140872A (en) 5,7-diaminopyrazolo[4,3-d]pyrimidines with pde-5 inhibitory activity, compositions containing such derivatives and the use of such derivatives in the treatment of hypertension and other disorders
WO2005046603A3 (en) Pyridine compounds
HUP0402588A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
IL179758A (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
WO2004071382A3 (en) Substituted heterocycles
WO2006110298A3 (en) 8-alkyl/aryl-4-aryl-2-n- (alkylamino)-n'-substituted-n'-cyanoguanidino-8h-pyrido[2,3-d]pyrimidin-7-one compounds and use thereof
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
EG24784A (en) Isoindolone derivatives, preparation process and intermediates of this process, their use as medicaments and pharmaceutical comprising them.
WO2004073628A3 (en) Novel compounds
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
WO2002074036A3 (en) Substituted benzopyranones as telomerase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003740426

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2492726

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004522410

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003740426

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 05/2004 ADD "DECLARATION UNDER RULE 4.17: - AS TO APPLICANT S ENTITLEMENT TO APPLY FOR AND BE GRANTED A PATENT (RULE 4.17(II))."

ENP Entry into the national phase

Ref document number: 2006014951

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10521540

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10521540

Country of ref document: US